APA (7th ed.) Citation

SC, S., RE, V., B, F., Y, Y., Z, H., KA, M., . . . W, X. (2024). The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. Cancer gene therapy, 31(4), 574. https://doi.org/10.1038/s41417-024-00735-1

Chicago Style (17th ed.) Citation

SC, Shin, Vickman RE, Filimon B, Yang Y, Hu Z, Mangold KA, Prabhakar BS, Schreiber H, and Xu W. "The Safety and Efficacy of Systemic Delivery of a New Liver-de-targeted TGFβ Signaling Inhibiting Adenovirus in an Immunocompetent Triple Negative Mouse Mammary Tumor Model." Cancer Gene Therapy 31, no. 4 (2024): 574. https://doi.org/10.1038/s41417-024-00735-1.

MLA (9th ed.) Citation

SC, Shin, et al. "The Safety and Efficacy of Systemic Delivery of a New Liver-de-targeted TGFβ Signaling Inhibiting Adenovirus in an Immunocompetent Triple Negative Mouse Mammary Tumor Model." Cancer Gene Therapy, vol. 31, no. 4, 2024, p. 574, https://doi.org/10.1038/s41417-024-00735-1.